Search Results

Is It Time to Reconsider Rituximab Dosing Regimens for Pemphigus Vulgaris?

• Authors : Ciolfi, Christian¹ (AUTHOR) ; Tartaglia, Jacopo¹ (AUTHOR); Alaibac, Mauro¹ (AUTHOR)

Subjects: *PEMPHIGUS vulgaris; *RITUXIMAB; *LYMPHOPROLIFERATIVE disorders

• Source: Antibodies (2073-4468). Mar2024, Vol. 13 Issue 1, p4. 4p.

Record details

Is dose-adjusted EPOCH-R the new standard for high-risk Burkitt lymphoma?

• Authors : Lim KJC; St Vincent's Hospital Melbourne, Melbourne, VIC, 3065 Australia. Electronic address: .; Filshie R

Subjects: Antineoplastic Combined Chemotherapy Protocols*/Antineoplastic Combined Chemotherapy Protocols*/Antineoplastic Combined Chemotherapy Protocols*/therapeutic use ; Burkitt Lymphoma*/Burkitt Lymphoma*/Burkitt Lymphoma*/drug therapy ; Lymphoma, Large B-Cell, Diffuse*/Lymphoma, Large B-Cell, Diffuse*/Lymphoma, Large B-Cell, Diffuse*/drug therapy EPOCH protocol

• Source: The Lancet. Haematology [Lancet Haematol] 2023 Dec; Vol. 10 (12), pp. e942-e943. Date of Electronic Publication: 2023 Oct 31.Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101643584 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Comprehensive genetic and functional analyses of Fc gamma receptors influence on response to rituximab therapy for autoimmunity.

• Authors : Robinson JI; Md Yusof MY ...

Subjects: Lupus Erythematosus, Systemic*/Lupus Erythematosus, Systemic*/Lupus Erythematosus, Systemic*/drug therapy ; Lupus Erythematosus, Systemic*/Lupus Erythematosus, Systemic*/Lupus Erythematosus, Systemic*/genetics ; Receptors, IgG*/Receptors, IgG*/Receptors, IgG*/drug effects

• Source: EBioMedicine [EBioMedicine] 2022 Dec; Vol. 86, pp. 104343. Date of Electronic Publication: 2022 Nov 11.Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101647039 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Applied Science & Technology Full Text (H.W. Wilson)

Record details

Long-term Effectiveness and Safety of Rituximab in Neuromyelitis Optica Spectrum Disorder and MOG Antibody Disease.

• Authors : Barreras P; From the Department of Neurology (P.B., E.S.V., A.G.F., K.C.F., C.A.P., S.D.N., E.M.M.C.R., P.A.C., E.S.S.), Johns Hopkins University School of Medicine, Baltimore, MD; and Department of Neurology (M.L.), Harvard University, Boston, MA.

Subjects: Agammaglobulinemia*/Agammaglobulinemia*/Agammaglobulinemia*/etiology ; Neuromyelitis Optica*/Neuromyelitis Optica*/Neuromyelitis Optica*/complications ; Neuromyelitis Optica*/Neuromyelitis Optica*/Neuromyelitis Optica*/drug therapy

• Source: Neurology [Neurology] 2022 Nov 29; Vol. 99 (22), pp. e2504-e2516. Date of Electronic Publication: 2022 Aug 31.Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 0401060 Publication Model: Print-Electronic Cited Medium:

Record details

[Rituximab for the treatment of generalised myasthenia gravis: experience in clinical practice].

• Authors : Martínez-Monte E; Hospital Clínico Universitario de Valencia, Valencia, España.; Gascón-Giménez F

Subjects: Myasthenia Gravis/Myasthenia Gravis/Myasthenia Gravis/*drug therapy ; Rituximab/Rituximab/Rituximab/*therapeutic use; Aged

• Source: Revista de neurologia [Rev Neurol] 2021 Nov 16; Vol. 73 (12), pp. 416-420.Publisher: Revista De Neurologia Country of Publication: Spain NLM ID: 7706841 Publication Model: Print Cited Medium: Internet ISSN: 1576-6578

Record details

Post-vaccination COVID Toes (Chilblains) Exacerbated by Rituximab Infusion Suggests Interferon Activation as Mechanism.

• Authors : Qiao JW; Department of Family and Community Medicine, Penn State Health Milton S. Hershey, Hershey, PA, USA.; Dan Y

Subjects: Chilblains*/Chilblains*/Chilblains*/pathology ; COVID-19*/COVID-19*/COVID-19*/prevention & control ; Interferons*

• Source: Military medicine [Mil Med] 2022 Oct 29; Vol. 187 (11-12), pp. e1480-e1482.Publisher: Oxford University Press Country of Publication: England NLM ID: 2984771R Publication Model: Print Cited Medium: Internet ISSN:

Record details

Protocol for an open-label, single-arm, multicentre clinical study to evaluate the efficacy and safety of rituximab in the first episode of paediatric idiopathic nephrotic syndrome.

• Authors : Liu J; Department of Nephrology, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China.; Shen Q

Subjects: Nephrotic Syndrome*/Nephrotic Syndrome*/Nephrotic Syndrome*/drug therapy ; Rituximab*/Rituximab*/Rituximab*/adverse effects; Child Nephrosis, congenital

• Source: BMJ open [BMJ Open] 2022 Oct 12; Vol. 12 (10), pp. e064216. Date of Electronic Publication: 2022 Oct 12.Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101552874 Publication Model: Electronic Cited Medium: Internet ISSN:

Record details

Acquired Hemophilia A following Pfizer-BioNTech SARS CoV-2 mRNA vaccine, successfully treated with prednisolone and rituximab.

• Authors : Murali A; School of Medicine, 1974University of Queensland, St Lucia, Queensland, Australia.; Cancer Care Services, Toowoomba Hospital, Toowoomba, Queensland, Australia.

Subjects: COVID-19*/COVID-19*/COVID-19*/prevention & control ; COVID-19 Vaccines*/COVID-19 Vaccines*/COVID-19 Vaccines*/adverse effects ; Hemophilia A*/Hemophilia A*/Hemophilia A*/drug therapy Factor 8 deficiency, acquired

• Source: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners [J Oncol Pharm Pract] 2022 Sep; Vol. 28 (6), pp. 1450-1453. Publisher: SAGE Publications Country of Publication: England NLM ID: 9511372 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Applied Science & Technology Full Text (H.W. Wilson)

Record details